Top 5 regulatory trends impacting Software as a Medical Device (SaMD)
As the biopharma space gets more competitive and the days of blockbuster drugs seem further in the rearview, biopharma companies are investing in digital to find new and innovative ways to differentiate themselves. These next-generation tools create more personalized experiences for patients, more information to guide clinical decision making and plenty of data for biopharma companies to use to continually improve therapies and to make a case for reimbursement.
Source: medcitynews.com
